Table III.

Ongoing Clinical Trials with Curcumin

Disease	Pts (#)	Phase	Dose; duration	PI (affiliation)	Start	Duration (month)
Cutaneous T cell lymphoma	28	II	8 g/day; 6 months	Madeleine Duvic; UTMDACC, USA	Apr 2012	24
NSCLC	32	I/II	4 g/day; 10 weeks	Zhongxing Liao; UTMDACC, USA	May 2012	24
Multiple myeloma	70	II	1 g/day; 6 monthsa	Robert Orlowski; UTMDACC, USA	Jan 2012	36
Advanced cancer	72	I	0.2 g/day; 28 daysa	Siqing Fu; UTMDACC, USA	Oct 2011	96
Head and neck cancer	32	I/II	4 g/day; 10 weeks	David Rosenthal; UTMDACC, USA	May 2012	24
Colon cancer	35	I	3.6 g/day; 7 daysa	Donald Miller; James Graham Brown, USA	Jan 2011	18
Colorectal cancer	40	I	4 g/day; 1 month	Gary Asher; UNC, USA	Nov 2010	12
Adenomatous polyps	50	II	3 g/day; 1 years	Francis Giardiello; JHU, USA	Sep 2010	60
Head and neck cancer	15	0	8 g/day; 3–4 weeks	Cherie-Ann Nathan; LS UHSC, USA	Jun 2010	24
Cervical dysplasia	16	I	0.5 g/day; 2 weeks	Lisa Flowers; Emory University, USA	Jan 2010	11
Colorectal cancer	30	I	5 capsules/day; 2–4 weeks	William Steward; UH, Leicester, UK	Jul 2009	6
Rectal cancer	45	II	8 g/daya	Sunil Krishnan; UTMDACC, USA	Jul 2008	60
Osteosarcoma	24	I/II	Dietary	Manish Agarwal; Tata Memorial Hospital, India	May 2008	60
Adenomatous polyps	50	–	4 pills/day; 12 months	Cruz-Correa; University of Puerto Rico	Nov 2007	96
Colorectal cancer	48	II	Dietary	Frank Meyskens; University of California, USA	Sep 2006	24
Adenomatous polyps	56	II	4 g/day; 4 months	Carmen Guerra; University of Pennsylvania, USA	Jul 2005	50
Advanced bowel cancer	42	I/II	–	William Steward, University of Leicester, UK	2012	24
				Joanna Reynolds, Cancer Research, UK
Radiation dermatitis	508	II	6 g/day; 4–7 weeks	Julie Ryan; University of Rochester, USA	Jan 2011	36
Radiation dermatitis	508	II/III	6 g/daya	Julie Ryan; University of Rochester, USA	Feb 2011	33
Radiation dermatitis	508	II/III	3 g/daya	Julie Ryan; University of Rochester, USA	Jan 2011	36
Irritable bowel syndrome	40	II	0.5 g/day; 4 weeksa	TimnaNaftali; Meir Medical Center, Israel	Apr 2011	8
Ulcerative colitis	50	III	5 g/daya	Alon Lang; Sheba Medical Center, Israel	July 2011	9
Rheumatoid arthritis	40	0	2–4 g/day; 16 weeks	Dinesh Khanna; University of California, USA	Jan 2010	12
Osteoarthritis	396	III	1.5 g/day; 28 days	VilaiKuptniratsaikul; MU, Thailand	Dec 2008	30
Ulcerative colitis	30	–	2 g/day; 2 monthsa	Iris Dotan; TASMC, Israel	Nov 2008	12
Alzheimer’s disease	26	II	4 g/day or 6 g/day	FaliPoncha; Jaslok Hospital, India	Oct 2009	8
Cognitive impairment	132	II	0.18 g/day; 18 months	Gary Small; University of California, USA	Jul 2011	60
LH optic neuropathy	70	III	0.5 g/day	Chuenkongkaew; MU, Thailand	May 2005	31
ESRF with renal transplant	20	I	Solution	KaijaSalmela; Helsinki University, Finland	Jan 2011	23
Abdominal aortic aneurysm	3500	III	4 g/day; 3 day	AmitGarg; LHRI, Canada	Nov 2011	36
Type 2 diabetes	200	IV	1.5 g/day; 12 months	SomlakChuengsamarn; SU, Thailand	Aug 2009	6
Type 2 diabetes	200	IV	1.5 g/day; 12 months	SomlakChuengsamarn; SU, Thailand	Jul 2009	6
Hyperprolactinoma	30	I	–	HalehYazdi; Mashhad University, Iran	Jul 2011	12

ESRF end-stage renal failure, LH optic neuropathy Leber’s hereditary optic neuropathy, NSCLC non–small cell lung cancer, JHU Johns Hopkins University, LHRI Lawson Health Research Institute, LSUHSC Louisiana State University Health Science Center, MU Mahidol University, SU Srinakharinwirot University, TASMC Tel Aviv Sourasky Medical Center, UH University Hospitals, UNC University of North Carolina, UTMDACC The University of Texas MD Anderson Cancer Center

www.clinicaltrials.gov

^aGiven in combination with other drugs